Axxelent Pharma Science Profile
Key Indicators
- Authorised Capital ₹ 175.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 131.53 Cr
as on 24-10-2024
- Company Age 5 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 175.96 Cr
as on 24-10-2024
- Revenue 111.74%
(FY 2023)
- Profit 14.74%
(FY 2023)
- Ebitda 38.39%
(FY 2023)
- Net Worth 58.25%
(FY 2023)
- Total Assets 86.64%
(FY 2023)
About Axxelent Pharma Science
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 175.00 Cr and a paid-up capital of Rs 131.53 Cr.
The company currently has active open charges totaling ₹175.96 Cr.
The Key Managerial Personnel (KMP) at Axxelent Pharma Science Private Limited India are Harihara P as CFO and Jagannathan Soundarya as Company Secretary. Kamlesh Phulwani, Hariharan Subramanian, Jitesh Devendra, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24110TN2019PTC131943
- Company No.
131943
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Oct 2019
- Date of AGM
14 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Axxelent Pharma Science?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harihara P  | CFO | 07-Sep-2021 | Current |
| Jitesh Devendra | Managing Director | 04-Dec-2020 | Current |
| Jagannathan Soundarya | Company Secretary | 16-Jul-2021 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Kamlesh Phulwani | Nominee Director | 10-Apr-2023 | Current |
| Hariharan Subramanian | Director | 01-Jul-2021 | Current |
| Chaitanya Devandra | Whole-Time Director | 22-Apr-2022 | Current |
| Sampath Devarajan | Director | 07-Oct-2019 | Current |
| Sreenivasa Bhimanatham | Whole-Time Director | 04-Dec-2020 | Current |
Financial Performance of Axxelent Pharma Science.
Axxelent Pharma Science Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 111.74% increase. The company also saw a substantial improvement in profitability, with a 14.74% increase in profit. The company's net worth Soared by an impressive increase of 58.25%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Axxelent Pharma Science?
In 2023, Axxelent Pharma Science had a promoter holding of 64.55% and a public holding of 35.45%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Axxinovar Pharma Private LimitedActive 3 years 5 months
Jitesh Devendra and Chaitanya Devandra are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 13 Dec 2023 | ₹2.46 M | Open |
Hdfc Bank Limited Creation Date: 30 Sep 2020 | ₹175.71 Cr | Open |
How Many Employees Work at Axxelent Pharma Science?
Axxelent Pharma Science has a workforce of 330 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Axxelent Pharma Science, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Axxelent Pharma Science's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
